Dose-ranging Study of Nemolizumab in Atopic Dermatitis

NCT03100344 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

226

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: Nemolizumab
DRUG: Placebo

Sponsor

Galderma R&D